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Abstract
Objectives: To date, the best treatment for Medication Related Osteonecrosis of the
jaw (MRONJ) is controversial. Recent studies suggest different therapies, considering
the stage of MRONJ; however, sometimes patients, although with remarkable exten-
sion of disease, cannot undergo surgery. The purpose of present preliminary study
was to evaluate the efficacy of conservative non-surgical treatment of MRONJ
lesions in a cohort of patients ineligible for surgery or refusing any surgical treatment
for stage II and III of MRONJ.
Materials and methods: Patients with MRONJ (staging II or III) ineligible for surgical
treatment were selected for a retrospective study. A conservative non-surgical therapy
(antibiotics and antiseptic) was administered for 1 year. Five scheduled checks were
performed to assess changes in signs and symptoms during the observational period.
Results: Our observation was carried out on 12 patients. Improvement of signs and
symptoms of disease were observed in population.
Conclusion: This study suggests that non-surgical treatment may be a valid therapeu-
tic option in patients ineligible for surgery. The sample size is small, further studies
should be carried out to satisfy the aim of a conservative non-surgical treatment pro-
tocol establishment.
K E YWORD S
conservative non-surgical therapy, MRONJ, oral diseases, osteonecrosis
1 | INTRODUCTION
Medication-related osteonecrosis of the jaw (MRONJ) is an adverse
drug reaction, characterized by progressive destruction of bone in
patients who underwent to bone-targeting agents associated with the
risk of MRONJ, in the absence of a previous radiation treatment
(Campisi et al., 2014; Fusco, Bedogni, Addeo, & Campisi, 2017).
To date, two main categories of drugs associated MRONJs are
recognized, acting differently to bone metabolism: antiresorptive
drugs (Bisphosphonates and Denosumab) and Antiangiogenic
(eg Vascular Endothelial Growth Factor inhibitors such as Bevacizumab,
Tyrosine Kinase inhibitors such as Sunitinib and mammalian Target
of Rapamycin inhibitors such as Everolimus) (Di Fede, Panzarella,
Mauceri, et al., 2018).
Etiology of MRONJ is multifactorial and pathogenesis remains
unknown (Ruggiero, Saxena, Tetradis, Aghaloo, & Ioannidou, 2018);
the patient's medical history, clinical examination, and radiological
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data are the only diagnostic and staging tools to approach and to face
this condition (Di Fede et al., 2018).
Since MRONJ is a multifactorial disease, it is difficult to develop
an etiological therapy; therefore, treatments can be surgical (Nisi
et al., 2018), with or without Growth Factors (Borsani et al., 2018),
and non-surgical. The non-surgical treatments include use of systemic
antibiotic therapy, also associated with hyperbaric oxygen therapy
(HBO) (Ceponis, Keilman, Guerry, & Freiberger, 2017), low-level laser
therapy (LLLT) (Mauceri, Panzarella, Maniscalco, et al., 2018), and topi-
cal ozone therapy (OT) (Ripamonti et al., 2012).
The surgical treatments can be divided into conservative
approaches (e.g., bone debridement, sequestrectomy) or more aggres-
sive therapy so surgical resections and jaw bone reconstruction,
where necessary (Ruggiero et al., 2018).
The best treatment for MRONJ is controversial, and there is not
yet an agreement about the recommended method; however, the cru-
cial point to face is the disease's progression by using infection control
means (Vescovi & Nammour, 2010).
In recent studies, authors suggest different therapies, considering
the stage of MRONJ (Iorio-Siciliano et al., 2018); however, sometimes
patients with remarkable extension of disease cannot undergo sur-
gery, for example, for pathological conditions, with high operative risk
of for neoplastic diseases considerably undermining the life expec-
tancy; in these cases, it could be indicated conservative non-surgical
therapy.
Operative risk can be approximately predicted using The Ameri-
can Society of Anesthesiologists (ASA) physical status classification
system. Table 1 shows the latest version as approved by the ASA
House of Delegates on October 15, 2014 (Doyle, Goyal, Bansal, &
Garmon, 2020).
Therefore, for patients classified as ASA 3 or 4, surgical treatment
of stage II and III of MRONJ (following SOCIETA' ITALIANA DI
PATOLOGIA E MEDICINA ORALE/SOCIETA' ITALIANA DI CHIRURGIA
MAXILLO-FACCILAE- SIPMO/SICMF- staging (Bedogni, Fusco, Agrillo, &
Campisi, 2012; Campisi et al., 2014) described in Table 2) could not
be considered the best treatment, not only for operative risk but
also because often they refused any surgical treatment for primary
pathology.
Therefore, the purpose of present preliminary retrospective study
was to evaluate the efficacy of conservative non-surgical treatment of
MRONJ lesions in a cohort of patients with high operative risk (ASA
3) or for refused any surgical treatment and stage II and III of MRONJ
(following SIPMO/SICMF staging [Bedogni et al., 2012; Campisi
et al., 2014]).
2 | MATERIALS AND METHODS
A retrospective analysis was carried out on patients referred to the
Section of Dentistry and Maxillofacial Surgery of University of Verona
(Italy), during the period 2012 to 2015; patients were selected for
the present study if they had (a) II and III stage MRONJ (following
SIPMO/SICMF staging [Bedogni et al., 2012; Campisi et al., 2014]),
(b) they refused surgical treatments or they were not eligible for them;
and (c) high operative risk (ASA 2–3 [Doyle et al., 2020]). We excluded
patients with pathological fracture of the jaw, who went to operation
and patients suffering from allergies.
TABLE 1 The American Society of Anesthesiologists (ASA)
physical status classification system
ASA 1 A normal healthy patient.
ASA 2 A patient with a mild systemic disease.
ASA 3 A patient with a severe systemic disease that is not life-
threatening.
ASA 4 A patient with a severe systemic disease that is a constant
threat to life.
ASA 5 A moribund patient who is not expected to survive without
the operation. The patient is not expected to survive
beyond the next 24 hours without surgery.
ASA 6 A brain-dead patient whose organs are being removed with
the intention of transplanting them into another patient.
TABLE 2 SIPMO/SICMF staging system
Stage I Focal ONJ
Clinical signs and symptoms: Bone exposure, sudden
dental mobility, nonhealing postextraction socket,
mucosal fistula, swelling, abscess formation, trismus
and gross mandible deformity hypoesthesia/
paraesthesia of the lips
CT signs: Increased bone density limited to the alveolar
bone region (trabecular thickening and focal
osteosclerosis), with or without the following signs:
Markedly thickened and sclerotic lamina dura,
persisting alveolar socket and cortical disruption
A asymptomatic
B symptomatic
Stage II Diffuse ONJ
Clinical signs and symptoms: Same as stage I
CT signs: Increased bone density extended to the basal
bone (diffuse osteosclerosis), with or without the
following signs: Prominence of the inferior alveolar
nerve canal, periosteal reaction, sinusitis, sequestra
formation and oro-antral fistula
A asymptomatic
B symptomatic
Stage III Complicated ONJ
Same as stage 2, with one or more of the following:
Clinical signs and symptoms: Extra-oral fistula,
displaced mandibular stumps and nasal leakage of
fluids
CT signs: Osteosclerosis of adjacent bones (zygoma and
hard palate), pathologic mandibular fracture and
osteolysis extending to the sinus floor
A asymptomatic
B symptomatic
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In all cases, MRONJ diagnoses and staging were made combining
medical history, clinical and radiological examination performed
by local multidisciplinary teams of specialists in oral medicine, oral
and maxillofacial surgery and radiology (following SIPMO/SICMF staging
[Bedogni et al., 2012; Campisi et al., 2014]). All patients signed informed
written consent about risks and benefits of treatment proposed.
All patients were followed for 12 months and timing of checks
was scheduled as follows:
t0 (baseline, first visit), t1 (1 month), t2 (4 months), t3 (7 months),
t4 (12 months).
- t0: first visit included general health assessment, accurate gen-
eral anamnesis about previous pathologies, allergies, previous surger-
ies, radiotherapy, and current and past drug treatments (exclusion
criteria). Clinical symptoms were investigated and clinical evidences
and risk factors of MRONJ (e.g., diabetes, concurrent use of steroid)
were deeply assessed as suggested by present day guidelines (Campisi
et al., 2014; Iorio-Siciliano et al., 2018).
Indeed, clinical signs and symptoms evaluated (Bedogni et al., 2012;
Campisi et al., 2014; Khan et al., 2015) were: bone exposure, mucosal
edema, mucosal rubor, dental infection, non-healing post extraction
socket, abscess, sudden tooth mobility, halitosis, mucous fistula, cutane-
ous fistula, rhinosinusitis, Vincent's sign, reported pain following VAS
scale.
Also, Panoramic radiograph and Computed Tomography (CT)
were carried out in order to diagnose MRONJ; radiological signs eval-
uated (Bedogni et al., 2012; Campisi et al., 2014; Ruggiero, Fantasia, &
Carlson, 2006) were: presence of bone sequestrum, diffuse osteo-
sclerosis, bone remodeling, periosteal reaction, pathological fracture
(excluded in this study), bone cortical interruption, rhinosinusitis.
Descriptive analysis of radiological data collected in t0 was carried
out. Clinical and radiological signs and symptoms were evaluated and
MRONJ was staged following SIPMO/SICMF recommendations
(Bedogni et al., 2012; Campisi et al., 2014) (Table 2).
A protocol of non-surgical therapy was administered to patients
according to the present day literature (Campisi et al., 2014;
Montebugnoli et al., 2007; Ristow, Otto, Troeltzsch, Hohlweg-
Majert, & Pautke, 2015; Vescovi & Nammour, 2010) as follows:
• Professional dental hygiene every 4 months for 1 year,
• Chlorohexidine (0.12%) first 7 days of every month, mouthwashes
two times a day for 1 year,
• Antibiotic treatment for 7 days of every month, whenever signs
of infection (suppuration) or pain occurred: amoxicillin + clavulanic
acid (875 mg + 125 mg) three times per day and metronidazole
(500 mg) three times per day.
When gastrointestinal disease related to the prolonged antibiotic
therapy was present, ciprofloxacin (500 mg) therapy two times per
day for 5 days was prescribed instead of amoxicillin+ clavulanic acid
(Moretti, Pelliccioni, Montebugnoli, & Marchetti, 2011).
- t1, t2, t3, t4: Visits at each time-point provided complete intra
and extra oral examination performed by the same surgeon. Clinical
signs and symptoms evaluated in t0 were scored at each time-point.
For evaluation of healing we followed Vescovi et al.(Vescovi &
Nammour, 2010) classification of “clinical success”:
Stage 0: complete mucosal healing, no symptoms, and no infec-
tion signs;
Stage I: presence of bone exposure, regression of infection signs,
regression of symptoms;
Stage II: presence of bone exposure with pain, infection, and
swelling in the lesion area, disappearance of cutaneous fistula, maxil-
lary sinus infection, fracture reparation;
Stage III: presence of bone exposure with pain, inflammation, sec-
ondary infection, cutaneous fistula, and pathological fracture.
Statistical analysis was performed using SPSS® Statistics 22
(IBM, Armonk, North Castle, NY), differences between and within
groups at different time-point have been tested by Kruskal-Wallis
one-way analysis of variance test, p value fixed at .05.
3 | RESULTS
For our study, we selected 12 patients (Table 3): 7 females and
5 males; the mean age was 81.5 years.
Prostate cancer was the most common diagnosis (33.3%),
followed by osteoporosis (16.6%), breast cancer (8.3%) and rheuma-
toid arthritis (8.3%) and multiple myeloma (8.3%). 5 patients (41.6%)
used Zoledronate intravenous, 3 patients (25%) used Alendronate per
os, 1 (8.3%) patients used Denosumab subcutaneous, 1 (8.3%) patient
used Trastuzumab, 1 (8.3%) patient used combined treatment with
Zoledronate and Alendronate, and 1 (8.3%) patient used combined
treatment with Denosumab and Risedronate.
Comorbidities were: high blood pressure, history of Transient
Ischemic Attack (TIA), pulmonary hypertension, history of stroke,
Parkinson's disease.
Spontaneous lesions occurred in 3 (25%) cases. A history of tooth
extraction at the site of necrosis was reported by 6 (50%) patients.
1 (8.3%) patient presented severe periodontal disease, in 1 (8.3%) case
MRONJ occurred for perimplantitis, in 1 (8.3%) patient had incongru-
ous dentures.
The site affected by MRONJ was the mandible in 11 (91.6%)
cases and the maxilla in 1 (8.4%) case. Clinically, 6 (50%) patients had
bone exposure. Edema and rubor were present in all patients (100%).
9 (75%) had mucous fistula, 4 (33.3%) presented with cutaneous
fistula. Halitosis was present in 83.3% of the patients. The pain symp-
toms was reported by 10 patients (Avg VAS 3/10), while the 2 patients
reported Vincent's sign.
Radiologic findings at t0 were: osteoslerosis (presented in all
cases), bone sequestrum (83.3%), bone remodeling (66.6%), periosteal
reaction (66.6%), rhinosinusitis (8.33%).
Some clinical and radiological images are showed in Figures 1 and 2.
MRONJ of all 12 patients was staged II and III, according to
the SICMF-SIPMO clinical and radiological staging system (Bedogni
et al., 2012).
No dropout from prescriptions were reported, further no patients
needed to change to ciprofloxacin. All patients were treated with only
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antibiotic with amoxicillin + clavulanic acid (875 mg + 125 mg) and
metronidazole (500 mg) three times per day and antiseptic therapies.
During the observation period, bone exposure slightly reduced and it
was found to be present in 33.3% of the sample at t4. Differences in
terms of bone exposure at different time-points were found to be not
statistically significant (p = .544); furthermore one patient expelled the
bone sequestrum spontaneously.
Rubor and edema found to be improved: at t2 16.6%
reported them, whereas in t4 signs were completely disappeared
(p = .00001).
Halitosis was present in 41.6% at t1 and in 8.3% at t2, no longer
detectable at t3 and t4. (p = .00001).
Mucous fistulas progressively recovered during the observation
period, found in 8.3% of the patients at t4. (p = .001); also cutaneous
fistulas were lowered to 2 cases (p = .6567).
TABLE 3 Patients' anamnestic data
Age (years) Sex ASA Medical conditions Related drug/s Affected bone MRONJ stage
1 70 M 2 Prostate cancer Zoledronate intravenous Maxilla 3
2 85 F 3 Osteoporosis Alendronate per os Mandible 2
3 95 F 3 Rheumatoid arthritis Denosumab and Risedronate Mandible 3
4 70 F 2 Breast cancer Zoledronate intravenous Mandible 2
5 84 F 2 Osteoporosis Zoledronate and alendronate Mandible 2
6 69 F 2 Multiple myeloma Zoledronate intravenous Mandible 3
7 85 F 3 Osteoporosis Alendronate per os Mandible 2
8 93 F 3 Osteoporosis Alendronate per os Mandible 2
9 78 M 2 Prostate cancer Denosumab Mandible 3
10 90 M 3 Prostate cancer Zoledronate intravenous Mandible 2
11 60 M 2 Prostate cancer Trastuzumab Mandible 3
12 80 M 2 Prostate cancer Zoledronate intravenous Mandible 2
F IGURE 1 Location: Lower
Jaw. Zolendronic Acid EV for
more than 3 years. Peri-
implantitis, bone remodeling and
cutaneous fistulas
F IGURE 2 Location: Upper Jaw. Zolendronic acid for more than
3 years. Bone exposure
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In one patient MRONJ was localized in upper jaw, in this
case rhinosinusitis (rhinorrhea) was present at t0. Medical treatment
completely solved this finding in t2. Differences within data collected
at different time-points are not statistically significant for this parame-
ter. (p = .541).
Pain showed a great enhancement: it was never reported at t4.
(p = .00001).
All our patients presented in t4 Stage 0 or Stage I following
Vescovi's classification (Vescovi & Nammour, 2010).
A summary of these results were reported in Table 4.
4 | DISCUSSIONS
To date, the best management of MRONJ is controversial; literature
promoted a stage-dependent management of the disease (Bermúdez-
Bejarano et al., 2017; Fliefel, Tröltzsch, Kühnisch, Ehrenfeld, &
Otto, 2015; Iorio-Siciliano et al., 2018; Ristow et al., 2015; Ruggiero
et al., 2014); indeed, the treatment protocol is case-dependent,
according to the condition stage and symptoms (AlDhalaan, BaQais, &
Al-Omar, 2020; Rosella et al., 2016).
In this retrospective study, we reported patients with II and III
stage of MRONJ and two of these were classified ASA 2. In itself,
ASA 2 does not represent a contraindication for surgical intervention,
indeed the real motivation for excluding these patients was their
unwillingness of undergoing a further surgery. They were affected by
cancers (breast and prostate) and stage II and III of MRONJ require
mild invasive surgical procedures, these issues were responsible for
inclusion of ASA 2 patients conservative treatment protocol for
MRONJ.
Conservative non-surgical treatment (maintaining good oral
hygiene, mouthwash, intraoral gels, analgesics, and antibiotics for dis-
continuing use) with clinical and radiological follow-up was found to be
usually reserved for patients in early asymptomatic stages. Moreover,
a recent literature review (AlDhalaan et al., 2020) reported that conser-
vative treatment could be implemented in patients who cannot
undergo surgical treatment, but though this approach may only pro-
vide temporary clinical healing of MRONJ in 70% of the cases. The
objective of this protocol is the control of infection in order to slow
the disease's progression, bone necrosis progression, and pain. Indeed,
it is difficult to obtain complete healing in advanced stage, thus healing
of MRONJ may be defined based on clinical examination, imaging find-
ings, or both (Beth-Tasdogan, Mayer, Hussein, & Zolk, 2017); in detail,
Vescovi et al.(Vescovi & Nammour, 2010) reported a classification of
“clinical success.” Therefore, it could be considered as positive result of
the treatment whether patients present Stage 0 or Stage I following
Vescovi's classification.
Moreover, in this study, patients treated were suffering from
other diseases (especially cancers in advanced stadium) and they
were of advanced age: therefore, conservative therapy seemed to be
the most suitable treatment in order to maintain a stable condition,
avoiding worsening of signs and symptoms, and ensuring an accept-
able quality of life.
Some authors demonstrated that non-surgical conservative ther-
apy may not necessarily lead to complete resolution of MRONJ, but it
may symptomatically provide long-term relief.
We are well aware about the heterogeneity of sample and we can
explain this because the aim of this preliminary study was to assess
the viability of this protocol in maintaining the signs and symptoms
of MRONJ under control without worsening of them. In good con-
science, this protocol represents for us the last one chance to ensure
a better quality of life to these patients, whenever it is possible, we
would look to recommend the surgical treatment.
Nevertheless, literature suggests that chlorhexidine mouthwashes
and an appropriate oral hygiene may reduce mouth bacterial count,
moreover reducing halitosis (Brignardello-Petersen, 2017; Erovic
Ademovski, Lingström, & Renvert, 2016). These results highlight the
importance of the use of chlorohexidine mouthwashes and profes-
sional dental hygiene in a prevention and conservative non-surgical
treatment protocol for MRONJ.
In addition, it has been documented in the literature that broad-
spectrum antibiotics as amoxicillin/clavulanic acid and metronidazole
are the first-line drugs (Campisi et al., 2014).
MRONJ-associated sinusitis usually requires a multidisciplinary
treatment (Procacci et al., 2018), however, in some case, signs and
symptoms may improve by using only medical treatment, such antibi-
otics, avoiding necessity of surgical treatment like FESS (Functional
Endoscopic Sinus Surgery) (Levine & Casiano, 2017) or Caldwell-Luc
TABLE 4 Trend of parameters during the observation period
Clinical examination t0 (first visit) t1 (1 month) t2 (4 months) t3 (7 months) t4 (12 months)
Mucosal edema 12 12 2 1 0****
Mucosal rubor 12 12 2 2 0****
Halitosis 10 5 1 0 0****
Mucous fistula 9 8 5 1 1***
Cutaneous fistola 4 3 2 3 2*
Bone exposure 6 5 5 5 4*
Rhinosinusitis 1 1 0 0 0*
Pain Avg. (vas scale) 3 1.5 0.9 0.4 0****
Note: *not statistically significant. **p < .05. ***p < .001. ****p < .00001.
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antrostomy (Datta, Viswanatha, & Shree, 2016). Although our data of
rhinosinusitis remission are not statistically significant because of poor
sample, we might assume that also this symptom may benefit by this
conservative treatment protocol. Opportunity of avoiding surgical
procedures in ineligible patients is a great chance in their manage-
ment; nevertheless, a larger sample is surely advisable.
Therefore, using this protocol, satisfying results were observed
in subjects affected by advanced MRONJ (stage II and III). All our
patients presented in t4 Stage 0 or Stage I following Vescovi's classifi-
cation (Vescovi & Nammour, 2010) and pain was never reported at t4.
(p = .00001).
These results suggest that many symptoms and signs, such
as mucosal inflammation and pain, could improve or remit with the
therapy administrated. This is encouraging for patients that cannot
undergo surgery, and they should be stressed during pre-protocol
talks and follow-up to improve compliance. Furthermore, regarding
such parameters, our results are highly statistically significant: this is a
great opportunity to improve the living conditions of patients affected
by MRONJ but non-suitable for surgery. However, the results of this
dosing regimen in the reduction of signs and symptoms of MRONJ
are encouraging, especially concerning the improvement of the quality
of life in palliative care.
Then, this study shows that non-surgical treatment may be a valid
option for MRONJ in patients ineligible for surgery, but sample size is
small; further studies on larger samples are required to define a proto-
col for conservative non-surgical treatment in MRONJ.
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